Prof. Dr Mohammad Amjad Kamal is a distinguished scientist affiliated with King Faisal University, where he leads a global research team. His extensive contributions to biochemistry research have resulted in over 750 publications in internationally renowned journals and 65 abstracts presented at international conferences. Notably, his work was pivotal in developing novel anti-Alzheimer agents, transitioning them from the laboratory to clinical trials in collaboration with Dr Nigel H. Greig, Chief of the Laboratory of Neurosciences at the National Institutes of Health (NIH), USA. In 1998, Prof. Kamal migrated to Australia and was awarded the prestigious U2000 Postdoctoral Fellowship by the University of Sydney, School of Molecular and Microbial Biosciences in 2000. This highly competitive three-year fellowship funded his research on the “Inhibition of amido phosphoribosyl transferase by new antifolates: Design and mechanism of action of purine antagonists.” He also collaborated on a molecular biology research project addressing Type 2 diabetes and Alzheimer’s disease at the University of Technology Sydney. He has been recognised as a highly cited top 1% researcher in the last 3 consecutive years (2023-2025) by Clarivate (https://www.webofscience.com/wos/author/record/J-2918-2014).